PN-943
Protagonist Therapeutics, Inc.
['ibd']
walter reinisch presents data from the phase 2 ideal rct of the oral, gut-restricted 4 7 integrin peptide antagonist pn-943 in patients with moderate to severe #ulcerativecolitis #ibd #uegweek #gitwitter 
The Lancet Gastroenterology & Hepatology publishes high-quality peer-reviewed research and reviews, comment, and news #gastroenterology #hepatology. IF=45.042